Quantification of Endothelial Thrombogenicity in Patients With Atrial Fibrillation "REMI-2"


Phase N/A Results N/A

Summary of Purpose

Atrial fibrillation (AF) is the most common cardiac arrhythmia. Because of its major impact on the general morbidity and risk of stroke, AF is a great concern for public health. Several mechanisms, including endothelial dysfunction and inflammatory processes, have been postulated as predisposing factors for AF, as well as for stroke. Both clinical and experimental studies highlight inflammation as a predisposing...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 19 February 2018.

1 Feb 2014 27 Apr 2016 1 Jan 2018 1 Jan 2018 1 Feb 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics




Trial Design

  • Allocation: Non-Randomized
  • Masking: Open Label
  • Purpose: Basic Science
  • Intervention: Parallel Assignment